Advances in treatment of Vogt-Koyanagi-Harada syndrome

Abstract

Vogt-Koyanagi-Harada(VKH)syndrome is an autoimmune disease attacking against pigmented cells, resulting in blindness and usually affecting multiple organs including ears, meninges, hair and skin. Correct diagnosis and immediate treatment in the early stage is vital to visual prognosis. Currently, corticosteroids is first-line drug. In addition, VKH patients refractory to corticosteroids can choose other treatment such as immunosuppressive agents and biological agents.

Keywords

• Vogt-Koyanagi-Harada syndrome
• corticosteroids
• immunosuppressive agent
• biological agent
• biological agent